Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties

Matrix Biology

Volumn 26, Issue 4, 2007, Pages 259-268

  Wilson, Christopher G ^b   Palmer, Ashley W ^a   Zuo, Fengrong ^c   Eugui, Elsie ^c   Wilson, Stacy ^c   Mackenzie, Rebecca ^c   Sandy, John D ^d   Levenston, Marc E ^a,b  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c ROCHE BIOSCIENCE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Aggrecanase; Cartilage; Degradation; Interleukin 1; Mechanical properties; MMP

Indexed keywords

AGGRECANASE; COLLAGEN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CATABOLISM; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLANT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHEAR STRENGTH;

AGGRECANS; ANIMALS; CARTILAGE; CARTILAGE, ARTICULAR; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-1; METALLOPROTEASES; MODELS, BIOLOGICAL; STRESS, MECHANICAL; TIME FACTORS;

BOVINAE;

EID: 34247479506     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2006.11.001     Document Type: Article

References (55)

1. Appleyard R.C., Burkhardt D., Ghosh P., Read R., Cake M., Swain M.V., and Murrell G.A. Topographical analysis of the structural, biochemical and dynamic biomechanical properties of cartilage in an ovine model of osteoarthritis. Osteoarthr. Cartil. 11 (2003) 65-77
2. Arner E.C., Hughes C.E., Decicco C.P., Caterson B., and Tortorella M.D. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthr. Cartil. 6 (1998) 214-228
3. Arner E.C., Pratta M.A., Decicco C.P., Xue C.B., Newton R.C., Trzaskos J.M., Magolda R.L., and Tortorella M.D. Aggrecanase. A target for the design of inhibitors of cartilage degradation. Ann. N. Y. Acad. Sci. 878 (1999) 92-107
4. Bau B., Gebhard P.M., Haag J., Knorr T., Bartnik E., and Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 46 (2002) 2648-2657
5. Beekman B., Verzijl N., de Roos J.A., and TeKoppele J.M. Matrix degradation by chondrocytes cultured in alginate: IL-1 beta induces proteoglycan degradation and proMMP synthesis but does not result in collagen degradation. Osteoarthr. Cartil. 6 (1998) 330-340
6. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., Chen J., Van Wart H., and Poole A.R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 99 (1997) 1534-1545
7. Bonassar L.J., Stinn J.L., Paguio C.G., Frank E.H., Moore V.L., Lark M.W., Sandy J.D., Hollander A.P., Poole A.R., and Grodzinsky A.J. Activation and inhibition of endogenous matrix metalloproteinases in articular cartilage: effects on composition and biophysical properties. Arch. Biochem. Biophys. 333 (1996) 359-367
8. Bonassar L.J., Sandy J.D., Lark M.W., Plaas A.H., Frank E.H., and Grodzinsky A.J. Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors. Arch. Biochem. Biophys. 344 (1997) 404-412
9. Chan P.S., Caron J.P., and Orth M.W. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am. J. Vet. Res. 66 (2005) 1870-1876
10. Chow G., and Knudson W. Characterization of promoter elements of the human HYAL-2 gene. J. Biol. Chem. 280 (2005) 26904-26912
11. Close D.R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60 Suppl 3 (2001) iii62-iii67
12. Eisenberg S.R., and Grodzinsky A.J. Swelling of articular cartilage and other connective tissues: electromechanochemical forces. J. Orthop. Res. 3 (1985) 148-159
13. Farndale R.W., Buttle D.J., and Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta 883 (1986) 173-177
14. Flannery C.R., Lark M.W., and Sandy J.D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J. Biol. Chem. 267 (1992) 1008-1014
15. Flannery C.R., Little C.B., Hughes C.E., and Caterson B. Expression and activity of articular cartilage hyaluronidases. Biochem. Biophys. Res. Commun. 251 (1998) 824-829
16. Flannery C.R., Little C.B., Caterson B., and Hughes C.E. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol. 18 (1999) 225-237
17. Flannery C.R., Zeng W., Corcoran C., Collins-Racie L.A., Chockalingam P.S., Hebert T., Mackie S.A., McDonagh T., Crawford T.K., Tomkinson K.N., LaVallie E.R., and Morris E.A. Autocatalytic cleavage of ADAMTS-4 (aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J. Biol. Chem. 277 (2002) 42775-42780
18. Fontana A., Hengartner H., Weber E., Fehr K., Grob P.J., and Cohen G. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int. 2 (1982) 49-53
19. Fosang A.J., Neame P.J., Last K., Hardingham T.E., Murphy G., and Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J. Biol. Chem. 267 (1992) 19470-19474
20. Fosang A.J., Last K., and Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J. Clin. Invest. 98 (1996) 2292-2299
21. Gao G., Westling J., Thompson V.P., Howell T.D., Gottschall P.E., and Sandy J.D. Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J. Biol. Chem. 277 (2002) 11034-11041
22. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., and Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 279 (2004) 10042-10051
23. Hopkins S.J., Humphreys M., and Jayson M.I. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin. Exp. Immunol. 72 (1988) 422-427
24. Jin M., and Grodzinsky A. Effect of electrostatic interactions between glycosaminoglycans on the shear stiffness of cartilage: a molecular model and experiments. Macromolecules 34 (2001) 8330-8339
25. Kashiwagi M., Enghild J.J., Gendron C., Hughes C., Caterson B., Itoh Y., and Nagase H. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J. Biol. Chem. 279 (2004) 10109-10119
26. Koshy P.J., Lundy C.J., Rowan A.D., Porter S., Edwards D.R., Hogan A., Clark I.M., and Cawston T.E. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 46 (2002) 961-967
27. Kuroki K., Stoker A.M., and Cook J.L. Effects of proinflammatory cytokines on canine articular chondrocytes in a three-dimensional culture. Am. J. Vet. Res. 66 (2005) 1187-1196
28. Laasanen M.S., Toyras J., Korhonen R.K., Rieppo J., Saarakkala S., Nieminen M.T., Hirvonen J., and Jurvelin J.S. Biomechanical properties of knee articular cartilage. Biorheology 40 (2003) 133-140
29. Little C.B., Flannery C.R., Hughes C.E., Mort J.S., Roughley P.J., Dent C., and Caterson B. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem. J. 344 Pt 1 (1999) 61-68
30. Little C.B., Hughes C.E., Curtis C.L., Janusz M.J., Bohne R., Wang-Weigand S., Taiwo Y.O., Mitchell P.G., Otterness I.G., Flannery C.R., and Caterson B. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 21 (2002) 271-288
31. Nguyen Q., Murphy G., Hughes C.E., Mort J.S., and Roughley P.J. Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem. J. 295 Pt 2 (1993) 595-598
32. Nixon J.S., Bottomley K.M., Broadhurst M.J., Brown P.A., Johnson W.H., Lawton G., Marley J., Sedgwick A.D., and Wilkinson S.E. Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro. Int. J. Tissue React. 13 (1991) 237-241
33. Oshita H., Sandy J.D., Suzuki K., Akaike A., Bai Y., Sasaki T., and Shimizu K. Mature bovine articular cartilage contains abundant aggrecan that is C-terminally truncated at Ala719-Ala720, a site which is readily cleaved by m-calpain. Biochem. J. 382 (2004) 253-259
34. Palmer A.W., Wilson C.G., Zuo F., Eugui E., and Levenston M.E. Altered Composition-Function Relationships During IL-1-Induced Cartilage Degradation. Trans. of 50th Annual Meeting of the ORS, San Francisco, CA (2004)
35. Patwari P., Kurz B., Sandy J.D., and Grodzinsky A.J. Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage. Arch. Biochem. Biophys. 374 (2000) 79-85
36. Patwari P., Gao G., Lee J.H., Grodzinsky A.J., and Sandy J.D. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthr. Cartil. 13 (2005) 269-277
37. Pratta M.A., Scherle P.A., Yang G., Liu R.Q., and Newton R.C. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum. 48 (2003) 119-133
38. Pratta M.A., Yao W., Decicco C., Tortorella M.D., Liu R.Q., Copeland R.A., Magolda R., Newton R.C., Trzaskos J.M., and Arner E.C. Aggrecan protects cartilage collagen from proteolytic cleavage. J. Biol. Chem. 278 (2003) 45539-45545
39. Reddy G.K., and Enwemeka C.S. A simplified method for the analysis of hydroxyproline in biological tissues. Clin. Biochem. 29 (1996) 225-229
40. Rieppo J., Toyras J., Nieminen M.T., Kovanen V., Hyttinen M.M., Korhonen R.K., Jurvelin J.S., and Helminen H.J. Structure-function relationships in enzymatically modified articular cartilage. Cells Tissues Organs 175 (2003) 121-132
41. Roughley P.J., Barnett J., Zuo F., and Mort J.S. Variations in aggrecan structure modulate its susceptibility to aggrecanases. Biochem. J. 375 (2003) 183-189
42. Sandy J.D., and Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem. J. 358 (2001) 615-626
43. Sandy J.D., Neame P.J., Boynton R.E., and Flannery C.R. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J. Biol. Chem. 266 (1991) 8683-8685
44. Sandy J.D., Flannery C.R., Neame P.J., and Lohmander L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J. Clin. Invest. 89 (1992) 1512-1516
45. Setton L.A., Elliott D.M., and Mow V.C. Altered mechanics of cartilage with osteoarthritis: human osteoarthritis and an experimental model of joint degeneration. Osteoarthr. Cartil. 7 (1999) 2-14
46. Smith C.L., MacDonald M.H., Tesch A.M., and Willits N.H. In vitro evaluation of the effect of dimethyl sulfoxide on equine articular cartilage matrix metabolism. Vet. Surg. 29 (2000) 347-357
47. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., Little C.B., Last K., Farmer P.J., Campbell I.K., Fourie A.M., and Fosang A.J. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434 (2005) 648-652
48. Sugimoto K., Iizawa T., Harada H., Yamada K., Katsumata M., and Takahashi M. Cartilage degradation independent of MMP/aggrecanases. Osteoarthr. Cartil. 12 (2004) 1006-1014
49. Sztrolovics R., Recklies A.D., Roughley P.J., and Mort J.S. Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1beta-stimulated catabolism. Biochem. J. 362 (2002) 473-479
50. Tortorella M., Pratta M., Liu R.Q., Abbaszade I., Ross H., Burn T., and Arner E. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J. Biol. Chem. 275 (2000) 25791-25797
51. Tortorella M.D., Malfait A.M., Deccico C., and Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthr. Cartil. 9 (2001) 539-552
52. Towle C.A., Hung H.H., Bonassar L.J., Treadwell B.V., and Mangham D.C. Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis. Osteoarthr. Cartil. 5 (1997) 293-300
53. Woessner J.F. The determination of hydroxyproline in tissue and protein samples containing small portions of this imino acid. Arch. Biochem. Biophys. 93 (1961) 440-447
54. Zhu W., Mow V.C., Koob T.J., and Eyre D.R. Viscoelastic shear properties of articular cartilage and the effects of glycosidase treatments. J. Orthop. Res. 11 (1993) 771-781
55. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., Dunstan C., Kollias G., Steiner G., Smolen J., and Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50 (2004) 277-290